This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by Integrated Community Oncology Network.
Recruitment status was:  Not yet recruiting
Information provided by:
Integrated Community Oncology Network Identifier:
First received: October 12, 2005
Last updated: October 13, 2005
Last verified: October 2005
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.

Condition Intervention Phase
Previously Treated Metastatic Non-Small Cell Lung Cancer Drug: Oxaliplatin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Integrated Community Oncology Network:

Primary Outcome Measures:
  • Efficacy

Secondary Outcome Measures:
  • Time to progression
  • Duration of response
  • Survival
  • Toxicity profile

Estimated Enrollment: 40
Detailed Description:
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.
  • Measurable disease
  • Good performance status (ECOG 0,1 or 2)

Exclusion Criteria:

  • Previously treated with Oxaliplatin or Navelbine
  • Symptomatic CNS metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00238849

Contact: Diane L Edwards, RN,OCN, CCRP 904-363-7471
Contact: Gloria Perez, RN, BSN, CCRP 904-739-7779

United States, Florida
Integrated Community Oncology Network Not yet recruiting
Jacksonville, Florida, United States, 32256
Contact: Diane Edwards, RN,OCN,CCRP    904-363-7471   
Contact: Gloria Perez, RN,BSN,OCN    904-739-7779   
Integrated Community Oncology Network Not yet recruiting
Orange Park, Florida, United States, 32073
Contact: Carla Malott, RN    904-272-3139   
Contact: Joan Ollie, BSN, RN    904-272-3139   
Principal Investigator: Thomas A Marsland, MD         
Sub-Investigator: Linda S Sylvester, MD         
Sub-Investigator: Kenneth Goldstein, MD         
Sponsors and Collaborators
Integrated Community Oncology Network
Principal Investigator: Thomas A Marsland, MD Integrated Community Oncology Network
  More Information Identifier: NCT00238849     History of Changes
Other Study ID Numbers: OX-03-087
Study First Received: October 12, 2005
Last Updated: October 13, 2005

Keywords provided by Integrated Community Oncology Network:
Non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Antineoplastic Agents, Phytogenic processed this record on September 21, 2017